{"created":"2023-05-15T16:35:27.494697+00:00","id":8356,"links":{},"metadata":{"_buckets":{"deposit":"8899b773-40b7-45e0-8226-cffc2cc17977"},"_deposit":{"created_by":2,"id":"8356","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"8356"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00008356","sets":["8:9"]},"author_link":["34054","34050","34053","34048","34049","34059","34057","34058","34051","34052","34055","34060","34045","34047","34046","34056"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2012","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"7","bibliographicPageStart":"1","bibliographicVolumeNumber":"2012","bibliographic_titles":[{"bibliographic_title":"Gastroenterology Research and Practice"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background. HCV infection is associated with lipid disorders because this virus utilizes the host lipid metabolism to sustain its life cycle. Several studies have indicated that higher concentrations of serum cholesterol and LDL before treatment are important predictors of higher rates of sustained virological response (SVR). However, most of these studies involved patients infected with HCV genotype 1. Thus, we performed a multi-institutional clinical study to evaluate the impact of lipid profiles on SVR rates in patients with HCV genotype 2. Methods. A total of 100 chronic hepatitis C patients with HCV genotype 2 who received peg-IFN alfa-2b and ribavirin therapy were consecutively enrolled. The significance of age, sex, BMI, AST level, ALT level, WBC, hemoglobin, platelet count, gamma-glutamyltransferase, total cholesterol level (TC), LDL level, HCV RNA, and histological evaluation was examined for SVR using logistic regression analysis. Results. The 100 patients infected with HCV genotype 2 were divided into 2 groups, an SVR group and a non-SVR group. Characteristics of each group were subsequently compared. There was no significant difference in the level of HCV RNA, BMI, platelet, TG, or stage of fibrosis between the groups. However, there were significant differences in the levels of TC and LDL-C. In multivariate logistic regression analysis using baseline characteristics, high TC level was an independent and significant risk factor (relative risk 18.59, P = 0.015) for SVR. Conclusion. Baseline serum total cholesterol levels should be considered when assessing the likelihood of sustained treatment response following the course of peg-IFN and ribavirin therapy in patients with chronic HCV genotype 2 infection.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Gastroenterology Research and Practice, 2012, 317580; 2012","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Hindawi Publishing Corporation"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1155/2012/317580","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2012 Naota Taura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited."}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"16876121","subitem_source_identifier_type":"ISSN"}]},"item_2_source_id_8":{"attribute_name":"EISSN","attribute_value_mlt":[{"subitem_source_identifier":"1687630X","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Taura, Naota"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ichikawa, Tatsuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miyaaki, Hisamitsu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kadokawa, Yoshiko"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tsutsumi, Takuya"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tsuruta, Shotaro"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kato, Yuji"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Inoue, Osami"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kinoshita, Noboru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ohba, Kazuo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kato, Hiroyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ohata, Kazuyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Masuda, Junichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hamasaki, Keisuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yatsuhashi, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakao, Kazuhiko"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-21"}],"displaytype":"detail","filename":"GRP2012_317580.pdf","filesize":[{"value":"556.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"GRP2012_317580.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/8356/files/GRP2012_317580.pdf"},"version_id":"4ae48a6b-3e12-4517-b843-fe6709ac2007"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"alanine aminotransferase","subitem_subject_scheme":"Other"},{"subitem_subject":"aspartate aminotransferase","subitem_subject_scheme":"Other"},{"subitem_subject":"cholesterol","subitem_subject_scheme":"Other"},{"subitem_subject":"gamma glutamyltransferase","subitem_subject_scheme":"Other"},{"subitem_subject":"low density lipoprotein cholesterol","subitem_subject_scheme":"Other"},{"subitem_subject":"peginterferon alpha2b plus ribavirin","subitem_subject_scheme":"Other"},{"subitem_subject":"virus RNA","subitem_subject_scheme":"Other"},{"subitem_subject":"adult","subitem_subject_scheme":"Other"},{"subitem_subject":"age distribution","subitem_subject_scheme":"Other"},{"subitem_subject":"alanine aminotransferase blood level","subitem_subject_scheme":"Other"},{"subitem_subject":"article","subitem_subject_scheme":"Other"},{"subitem_subject":"aspartate aminotransferase blood level","subitem_subject_scheme":"Other"},{"subitem_subject":"blood sampling","subitem_subject_scheme":"Other"},{"subitem_subject":"body mass","subitem_subject_scheme":"Other"},{"subitem_subject":"cholesterol blood level","subitem_subject_scheme":"Other"},{"subitem_subject":"clinical study","subitem_subject_scheme":"Other"},{"subitem_subject":"female","subitem_subject_scheme":"Other"},{"subitem_subject":"gamma glutamyl transferase blood level","subitem_subject_scheme":"Other"},{"subitem_subject":"genotype","subitem_subject_scheme":"Other"},{"subitem_subject":"hepatitis C","subitem_subject_scheme":"Other"},{"subitem_subject":"Hepatitis C virus","subitem_subject_scheme":"Other"},{"subitem_subject":"histology","subitem_subject_scheme":"Other"},{"subitem_subject":"human","subitem_subject_scheme":"Other"},{"subitem_subject":"leukocyte count","subitem_subject_scheme":"Other"},{"subitem_subject":"major clinical study","subitem_subject_scheme":"Other"},{"subitem_subject":"male","subitem_subject_scheme":"Other"},{"subitem_subject":"multicenter study","subitem_subject_scheme":"Other"},{"subitem_subject":"retrospective study","subitem_subject_scheme":"Other"},{"subitem_subject":"risk factor","subitem_subject_scheme":"Other"},{"subitem_subject":"thrombocyte count","subitem_subject_scheme":"Other"},{"subitem_subject":"treatment response","subitem_subject_scheme":"Other"},{"subitem_subject":"viremia","subitem_subject_scheme":"Other"},{"subitem_subject":"virus load","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2"}]},"item_type_id":"2","owner":"2","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-03-27"},"publish_date":"2013-03-27","publish_status":"0","recid":"8356","relation_version_is_last":true,"title":["Baseline Serum Cholesterol Is Associated with a Response to Pegylated Interferon Alfa-2b and Ribavirin Therapy for Chronic Hepatitis C Genotype 2"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T02:07:10.614381+00:00"}